Articles related to Hepatology

This “1-Minute Consult” discusses what constitutes bile duct dilation, clinical evaluation, imaging options for workups, clinical approach to the evaluation, and take-home points, along with figures, tables, info, and metrics on the condition.

We already shared the story about the financial advantage of AI being used in colonoscopies — here is a related story featuring key takeaways regarding the importance of screening in younger people, new techniques such as linked color imaging, and the non-invasive modality MRI colonography.

Capsule endoscopy, also known as wireless capsule endoscopy or video capsule endoscopy, is a noninvasive procedure that uses a swallowed capsule-shaped miniature camera for direct visual and diagnostic evaluation of various gastrointestinal (GI) diseases. Although originally intended as a tool to examine the small intestine, which is mostly beyond the reach of conventional endoscopy, capsule endoscopy is now being used to examine the entire length of the GI tract.

Primary hyperparathyroidism (PHPT) is associated with increased risk for fractures, cardiovascular disease, kidney disease, and cancer, along with increased mortality. In mild PHPT with modest hypercalcemia and without known morbidities, parathyroidectomy is debated because no long-term randomized trials have been performed related to it.

A potentially practice-changing clinical trial for first line therapy is the first to show that the combination of two immunotherapy medications is an effective treatment for hepatocellular carcinoma (HCC). The HIMALAYA study evaluated combination immunotherapy (IO-IO), durvalumab with tremelimumab, as frontline therapy in patients with unresectable HCC. Overall survival was significantly improved with the IO-IO combination compared with sorafenib monotherapy (16.4 vs 13.8 months; hazard ratio [HR], 0.78; 96% CI, 0.65-0.92; P =.0035). Early results of the phase three LAUNCH trial are also promising. This trial compared the combination of lenvatinib with transarterial chemoembolization (TACE) to lenvatinib alone in an Asian population with advanced HCC. The lenvatinib-TACE group achieved a higher median overall survival (17.8 vs. 11.5 months and median progression-free survival (10.6 vs. 6.4 months). Muhammad Shaalan Beg, MD, director for GI Medical Oncology at UT Southwestern Medical Center in Dallas summarizes these and other takeaways from emerging research on advanced HCC presented at the recent ASCO GI Symposium.

An interesting case study in BRASH (bradycardia, renal failure, atrioventricular blockade, shock, and hyperkalemia) syndrome highlights Rare Disease Day, which took place on 2/28/22. After reviewing the patient’s history and symptoms, would you agree on the diagnosis?